Molecular and Cellular Biochemistry (2019) 450:209–210
https://doi.org/10.1007/s11010-018-3482-x

CORRECTION

Correction to: ACE2, CALM3 and TNNI3K polymorphisms as potential disease modifiers in hypertrophic and dilated cardiomyopathies

Amit Kumar[1] · Bindu Rani[1] · Rajni Sharma[2] · Gurjeet Kaur[4] · Rishikesh Prasad[1] · Ajay Bahl[3] · Madhu Khullar[1]

Published online: 28 November 2018

Correction to: Mol Cell Biochem (2018) 438:167–174
https://doi.org/10.1007/s11010-017-3123-9

In the original publication of the article, the location and rs number of TNNI3K mouse SNP (3784 C>T) (rs49812611) has been mentioned inadvertently in place of its human homologue. The correct information for human SNP is rs760769780 located at position 74436534, resulting in (G>A) change in human TNNI3K gene.

Therefore, TNNI3K (3784 C>T, rs 49812611) should be read as TNNI3K 74436534 G>A, rs number 760769780 in the text. The correct rs number (760769780) and location of gene (74436534) have been provided in the corrected Tables 2 and 3.

The original article can be found online at https://doi.org/10.1007/s11010-017-3123-9.

✉ Madhu Khullar
madhu.khullar@gmail.com

[1] Department of Experimental Medicine and Biotechnology, PGIMER, Lab No 2009, Research Block B, Chandigarh 160012, India

[2] Department of Otolaryngology, PGIMER, Chandigarh, India

[3] Department of Cardiology, PGIMER, Chandigarh, India

[4] Department of Endocrinology, PGIMER, Chandigarh, India

Table 2 Genotype frequency of *ACE2*, *TNNI3K* and *CALM3* genes in HCM, DCM patients and controls

Polymorphisms	HCM ($n=130$)	Control ($n=236$)	OR (95% CI)	p value
ACE2 (7160726 C>G)	CC = 81 (62.3)	CC = 146 (61.9)	0.86 (0.53–1.40)	0.62
	CG = 36 (27.7)	CG = 75 (31.8)	1.56 (0.71–3.44)	0.30
	GG = 13 (10)	GG = 15 (6.4)		
TNN13K (74436534 G>A)	GG = 77 (62.3)	GG = 161 (68.2)	1.19 (0.74–1.89)	0.47
	GA = 42 (32.3)	GA = 74 (31.4)	23(2.91–181.38)	0.000056
	AA = 11 (8.5)	AA = 01 (0.4)		
CALM3 (−34T>A)	TT = 68 (52.3)	TT = 151 (63.7)	1.32 (0.84–2.08)	0.25
	TA = 51 (39.2)	TA = 86 (36.3)	Infinite	0.000048
	AA = 11 (8.5)	AA = 0 (0)		
Polymorphisms	DCM ($n=161$)	Control ($n=236$)	OR (95% CI)	p value
ACE2 (7160726 C>G)	CC = 116 (72)	CC = 133 (56.4)	0.63 (0.40–1.00)	0.05
	CG = 41 (25.5)	CG = 74 (31.4)	0.15 (0.05–0.46)	0.0001
	GG = 4 (2.5)	GG = 29 (12.30)		
TNN13K (74436534 G>A)	GG = 111 (68.9)	GG = 161 (68.2)	0.8 (0.51–1.26)	0.36
	GA = 41 (25.5)	GA = 74 (31.4)	13.05(1.63–104.50)	0.002
	AA = 9 (5.6)	AA = 1 (0.4)		
CALM3 (−34T>A)	TT = 99 (61.5)	TT = 151 (63.7)	0.89 (0.58–1.38)	0.66
	TA = 50 (31.1)	TA = 86 (36.3)	Infinite	0.000023
	AA = 12 (7.5)	AA = 0 (0)		

Table 3 *ACE2*, *TNNI3K* and *CALM3* gene allele frequencies in HCM and DCM patients and controls

Polymorphisms	HCM ($n=130$)	Control ($n=236$)	OR (95% CI)	p value
ACE2 (7160726 C>G)	C = 198 (0.76)	C = 367 (0.78)	1.09 (0.76–1.57)	0.64
	G = 62 (0.24)	G = 105 (0.22)		
TNN13K (74436534 G>A)	G = 196 (0.75)	G = 396 (0.84)	1.70 (1.17–2.47)	0.005
	A = 64 (0.25)	A = 76 (0.16)		
CALM3 (−34T>A)	T = 187 (0.72)	T = 387 (0.82)	1.76 (1.23–2.52)	0.002
	A = 73 (0.28)	A = 85 (0.18)		
Polymorphisms	DCM ($n=161$)	Control ($n=236$)	OR (95% CI)	p value
ACE2 (7160726 C>G)	C = 273 (0.85)	C = 340 (0.72)	0.46 (0.32–0.66)	0.00003
	G = 49 (0.15)	G = 132 (0.28)		
TNN13K (74436534 G>A)	G = 396 (0.84)	G = 263 (0.82)	1.17 (0.80–1.69)	0.44
	A = 76 (0.16)	A = 59 (0.18)		
CALM3 (−34T>A)	T = 248 (0.77)	T = 388 (0.82)	1.36 (0.95–1.93)	0.08
	A = 74 (0.23)	A = 86 (0.18)		